The asthma-COPD overlap syndrome: Towards a revised taxonomy of chronic airways diseases?

The Lancet Respiratory Medicine

Volumn 3, Issue 9, 2015, Pages 719-728

  Bateman, Eric D ^a   Reddel, Helen K ^b   van Zyl Smit, Richard N ^a   Agusti, Alvar ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; MONTELUKAST; OMALIZUMAB; RECOMBINANT INTERLEUKIN 13; RECOMBINANT INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 5; ROFLUMILAST; TIOTROPIUM BROMIDE;

ASTHMA; ASTHMA CHRONIC OBSTRUCTIVE LUNG DISEASE OVERLAP SYNDROME; ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; MEDICAL HISTORY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT PARAMETERS; REVIEW; SMOKING; SPIROMETRY; TAXONOMY; TREATMENT RESPONSE; ADULT; CLASSIFICATION; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME;

ADULT; ASTHMA; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYNDROME;

EID: 84941176876     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00254-4     Document Type: Review

References (88)

1. Ioachimescu OC, Teodorescu M Integrating the overlap of obstructive lung disease and obstructive sleep apnoea: OLDOSA syndrome. Respirology 2013, 18:421-431.
2. Zeki AA, Schivo M, Chan A, Albertson TE, Louie S The asthma-COPD overlap syndrome: a common clinical problem in the elderly. J Allergy (Cairo) 2011, 2011:861926.
3. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS) GINA-GOLD, (accessed May 5, 2015). http://www.goldcopd.org/asthma-copd-overlap.html.
4. Global strategy for asthma management and prevention GINA, (accessed May 5, 2015). http://www.ginasthma.org.
5. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD, (accessed May 5, 2015). http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf.
6. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013, 22:117-121.
7. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007, 14(suppl B):5B-32B.
8. Nagai A [Guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 3rd edition]. Nihon Rinsho 2011, 69:1729-1734. (in Japanese).
9. Kankaanranta H, Harju T, Kilpelainen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol 2015, 116:291-307.
10. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res 2011, 12:127.
11. de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PloS One 2013, 8:e62985.
12. Andersen H, Lampela P, Nevanlinna A, Saynajakangas O, Keistinen T High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J 2013, 7:342-346.
13. O'Neil SE, Lundback B, Lotvall J Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities. J Proteomics 2011, 75:192-201.
14. Mannino DM, Gagnon RC, Petty TL, Lydick E Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000, 160:1683-1689.
15. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003, 124:474-481.
16. Pleasants RA, Ohar JA, Croft JB, et al. Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD 2014, 11:256-266.
17. Mannino DM Coexisting asthma and COPD: confused clinicians or poor prognosticator?. Chest 2008, 134:1-2.
18. Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 2011, 48:279-285.
19. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007, 132:1882-1889.
20. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001, 164:744-748.
21. Shirtcliffe P, Marsh S, Travers J, Weatherall M, Beasley R Childhood asthma and GOLD-defined chronic obstructive pulmonary disease. Intern Med J 2012, 42:83-88.
22. Guerra S, Sherrill DL, Kurzius-Spencer M, et al. The course of persistent airflow limitation in subjects with and without asthma. Respir Med 2008, 102:1473-1482.
23. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003, 58:322-327.
24. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
25. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012, 67:701-708.
26. Hanania NA, Sharafkhaneh A, Celli B, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res 2011, 12:6.
27. Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med 2014, 189:1022-1030.
28. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008, 63:761-767.
29. Svanes C, Sunyer J, Plana E, et al. Early life origins of chronic obstructive pulmonary disease. Thorax 2010, 65:14-20.
30. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003, 349:1414-1422.
31. Gibson PG, Simpson JL The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64:728-735.
32. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750.
33. Fu JJ, McDonald VM, Gibson PG, Simpson JL Systemic inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res 2014, 6:316-324.
34. Johannessen A, Omenaas E, Bakke P, Gulsvik A Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. Int J Tuberc Lung Dis 2005, 9:926-932.
35. Ohar JA, Sadeghnejad A, Meyers DA, Donohue JF, Bleecker ER Do symptoms predict COPD in smokers?. Chest 2010, 137:1345-1353.
36. de Marco R, Accordini S, Cerveri I, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007, 175:32-39.
37. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005, 128:2099-2107.
38. Golpe R, Sanjuan Lopez P, Cano Jimenez E, Castro Anon O, Perez de Llano LA Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 2014, 50:318-324.
39. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015, 385:1789-1798.
40. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS) GINA-GOLD, (accessed June 14, 2015). http://www.ginasthma.org/local/uploads/files/ACOS_2015.pdf.
41. Global strategy for asthma management and prevention GINA, (accessed June 14, 2015). http://www.ginasthma.org.
42. Third Expert Panel on the Diagnosis and Management of Asthma. Expert panel report 3: Guidelines for the diagnosis and management of asthma, 2007 National Asthma Education and Prevention Program, (accessed June 16, 2015). http://www.nhlbi.nih.gov/files/docs/guidelines/asthsumm.pdf.
43. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155:179-191.
44. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 2013, 6:197-219.
45. Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012, 48:331-337.
46. British guideline on the management of asthma. A national clinical guideline British Thoracic Society, Scottish Intercollegiate Guidelines NetworkScottish Intercollegiate Guidelines Network, (accessed June 16, 2015). https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/.
47. American Thoracic Society. Am Rev Respir Dis 1991, 144:1202-1218. Lung function testing: selection of reference values and interpretative strategies.
48. Miravitlles M, Calle M, Soler-Cataluna JJ Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol 2012, 48:86-98.
49. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
50. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
51. Brusselle GG, Maes T, Bracke KR Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013, 19:977-979.
52. Brusselle G Why doesn't reducing exacerbations decrease COPD mortality?. Lancet Respir Med 2014, 2:681-683.
53. Chung KF New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013, 1:639-652.
54. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
55. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
56. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006, 96:679-686.
57. Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med 2015, 3:367-376.
58. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012, 367:1198-1207.
59. Agusti A, Anto JM, Auffray C, et al. Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med 2015, 191:391-401.
60. Agusti A The path to personalised medicine in COPD. Thorax 2014, 69:857-864.
61. Beasley MB Smoking-related small airway disease-a review and update. Adv Anat Pathol 2010, 17:270-276.
62. Vanfleteren LE, Kocks JW, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?. Thorax 2014, 69:72-79.
63. Shirtcliffe P, Weatherall M, Travers J, Beasley R The multiple dimensions of airways disease: targeting treatment to clinical phenotypes. Curr Opin Pulm Med 2011, 17:72-78.
64. Jameson JL, Longo DL Precision medicine-personalized, problematic, and promising. N Engl J Med 2015, 372:2229-2234.
65. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009, 34:812-818.
66. Lee J, Cho MH, Hersh CP, et al. Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. Respir Res 2014, 15:113.
67. Soler Artigas M, Loth DW, Wain LV, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet 2011, 43:1082-1090.
68. Castaldi PJ, San Jose Estepar R, Mendoza CS, et al. Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers. Am J Respir Crit Care Med 2013, 188:1083-1090.
69. Dirksen A, MacNee W The search for distinct and clinically useful phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1045-1046.
70. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.
71. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010, 36:531-539.
72. Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 2015, 12:303-312.
73. Kim DK, Cho MH, Hersh CP, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 186:1238-1247.
74. Kong X, Cho MH, Anderson W, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 2011, 183:43-49.
75. Manichaikul A, Hoffman EA, Smolonska J, et al. Genome-wide study of percent emphysema on computed tomography in the general population. The multi-ethnic study of atherosclerosis lung/SNP health association resource study. Am J Respir Crit Care Med 2014, 189:408-418.
76. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:418-424.
77. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 2012, 7:283-289.
78. Martinez FD The origins of asthma and chronic obstructive pulmonary disease in early life. Proc Am Thorac Soc 2009, 6:272-277.
79. van den Berge M, Vonk JM, Gosman M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J 2012, 40:1098-1105.
80. Brutsche MH, Downs SH, Schindler C, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006, 61:671-677.
81. Orie NGM, Sluiter HJ Bronchitis: an international symposium 1962, Royal van Gorcum, Assen, Netherlands.
82. Sluiter HJ, Koeter GH, de Monchy JG, Postma DS, de Vries K, Orie NG The Dutch hypothesis (chronic non-specific lung disease) revisited. Eur Respir J 1991, 4:479-489.
83. Vermeire PA, Pride NB A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 1991, 4:490-496.
84. Postma DS, Kerkhof M, Boezen HM, Koppelman GH Asthma and chronic obstructive pulmonary disease: common genes, common environments?. Am J Respir Crit Care Med 2011, 183:1588-1594.
85. Smolonska J, Koppelman GH, Wijmenga C, et al. Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis. Eur Respir J 2014, 44:860-872.
86. Hardin M, Cho M, McDonald ML, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 2014, 44:341-350.
87. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of geno40mic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015, 191:758-766.
88. Diez D, Agusti A, Wheelock CE Network analysis in the investigation of chronic respiratory diseases. From basics to application. Am J Respir Crit Care Med 2014, 190:981-988.